BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 30936125)

  • 1. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
    Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
    Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity.
    Kaltenmeier CT; Vollmer LL; Vernetti LA; Caprio L; Davis K; Korotchenko VN; Day BW; Tsang M; Hulkower KI; Lotze MT; Vogt A
    J Pharmacol Exp Ther; 2017 Apr; 361(1):39-50. PubMed ID: 28154014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression profiles and roles of inducible DUSPs and ERK1/2-specific constitutive DUSP6 and DUSP7 in microglia.
    Ham JE; Oh EK; Kim DH; Choi SH
    Biochem Biophys Res Commun; 2015 Nov; 467(2):254-60. PubMed ID: 26435497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance.
    Zandi Z; Kashani B; Alishahi Z; Pourbagheri-Sigaroodi A; Esmaeili F; Ghaffari SH; Bashash D; Momeny M
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):57-70. PubMed ID: 34981193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
    Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
    Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The promise of signal transduction in genetically driven sarcomas of the nerve.
    Kim A; Pratilas CA
    Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.
    Patel AV; Chaney KE; Choi K; Largaespada DA; Kumar AR; Ratner N
    EBioMedicine; 2016 Jul; 9():110-119. PubMed ID: 27333032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
    Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
    Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
    Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
    Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Status of
    Peacock JD; Pridgeon MG; Tovar EA; Essenburg CJ; Bowman M; Madaj Z; Koeman J; Boguslawski EA; Grit J; Dodd RD; Khachaturov V; Cardona DM; Chen M; Kirsch DG; Maina F; Dono R; Winn ME; Graveel CR; Steensma MR
    Cancer Res; 2018 Jul; 78(13):3672-3687. PubMed ID: 29720369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.
    Wu QN; Liao YF; Lu YX; Wang Y; Lu JH; Zeng ZL; Huang QT; Sheng H; Yun JP; Xie D; Ju HQ; Xu RH
    Cancer Lett; 2018 Jan; 412():243-255. PubMed ID: 29050982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCI, an inhibitor of the DUSP1 and DUSP6 dual specificity phosphatases, enhances P2X7 receptor expression in neuroblastoma cells.
    Benito-León M; Gil-Redondo JC; Perez-Sen R; Delicado EG; Ortega F; Gomez-Villafuertes R
    Front Cell Dev Biol; 2022; 10():1049566. PubMed ID: 36589747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.
    Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL
    Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
    Liu F; Gore AJ; Wilson JL; Korc M
    PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor.
    Li XX; Zhang SJ; Chiu AP; Lo LH; Huang J; Rowlands DK; Wang J; Keng VW
    Cancer Med; 2018 Sep; 7(9):4791-4800. PubMed ID: 30112810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells.
    Fischer-Huchzermeyer S; Dombrowski A; Hagel C; Mautner VF; Schittenhelm J; Harder A
    Am J Pathol; 2017 Jul; 187(7):1623-1632. PubMed ID: 28502478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.
    Byer SJ; Eckert JM; Brossier NM; Clodfelder-Miller BJ; Turk AN; Carroll AJ; Kappes JC; Zinn KR; Prasain JK; Carroll SL
    Neuro Oncol; 2011 Jan; 13(1):28-41. PubMed ID: 21075781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.